Douglas A. Dachille - 20 Jun 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Douglas A. Dachille
Issuer symbol
BBIO
Transactions as of
20 Jun 2025
Net transactions value
$0
Form type
4
Filing time
24 Jun 2025, 18:55:41 UTC
Previous filing
23 May 2025
Next filing
03 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dachille Douglas A. Director C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO /s/ Douglas A. Dachille 24 Jun 2025 0001652908

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Award $0 +6,589 $0.000000 6,589 20 Jun 2025 Direct F1, F2
holding BBIO Common Stock 20,000 20 Jun 2025 By The Dachille 2012-1 Family Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (Right to Buy) Award $0 +8,425 $0.000000 8,425 20 Jun 2025 Common Stock 8,425 $41.73 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
F2 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3 These shares are owned directly by The Dachille 2012-1 Family Trust for the benefit of the reporting person's children, for which the reporting person's spouse is the trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F4 One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.